ライフサイエンスコーパス: length of stay

1 l therapy treatment associated with hospital length of stay.

2 reased the time to effective therapy and the length of stay.

3 ality and readmission and risk-adjusted mean length of stay.

4 C per 1000 admissions, 30-day mortality, and length of stay.

5 verse events, and resource measures like ICU length of stay.

6 ary end points were 30-day total charges and length of stay.

7 The primary outcome was hospital length of stay.

8 s defined by intensive care use and hospital length of stay.

9 care unit (ICU) admission, and ICU/hospital length of stay.

10 induction is beneficial in reducing hospital length of stay.

11 ventilator-free days, ICU, and the hospital length of stay.

12 c characteristics, reason for admission, and length of stay.

13 els in adult ICUs and reporting mortality or length of stay.

14 ase in hospital mortality, dialysis use, and length of stay.

15 thoracic intensive care unit could influence length of stay.

16 gth of stay, and post-ICU discharge hospital length of stay.

17 , and intensive care unit (ICU) and hospital length of stay.

18 utcomes include duration of delirium and ICU length of stay.

19 ciated sleep intervention with a reduced ICU length of stay.

20 tically reviewed models to predict adult ICU length of stay.

21 tics, and leading to a reduction in hospital length of stay.

22 mechanical ventilation, ICU utilization, and length of stay.

23 s of $1685, and a mean reduction of 1.5 days length of stay.

24 he costs of prevention and any difference in length of stay.

25 tion were associated with increased hospital length of stay.

26 mechanical ventilation, ICU utilization, and length of stay.

27 .08) with no differences in ICU and hospital length of stay.

28 in worse postoperative outcomes and greater lengths of stay.

29 tio, 0.84; 95% CI, 0.79-0.93; p < 0.001) and length of stay (-0.7 d; 95% CI, -1.1 to -0.2; p < 0.001)

30 In-hospital mortality was 33.2%, with median length of stay 11 days (interquartile range, 5-22), and

31 ters (n = 1752), there was no improvement in length of stay (13.3 vs 12.4 days, P = 0.287), severe co

32 s ratio, 1.63; 95% CI, 1.01-2.63) and longer length of stay (2.25 d; CI, 0.58-3.92).

33 eadmissions tended to have shorter index ICU lengths of stay (2 vs 3 d; p = 0.05) and a shorter durat

34 in children with delirium (adjusted relative length of stay, 2.3; CI = 2.1-2.5; p < 0.001), as was du

35 readmission (odds ratio for log-transformed length of stay: 2.39 [99% confidence interval: 2.31 to 2

36 .2%] and six [3.9%] patients; p = 0.77), ICU length of stay (24.7 +/- 22.9 and 23 +/- 23.8 d; p = 0.5

37 use on postoperative healthcare utilization (length of stay, 30-d readmission, and discharge destinat

38 Secondary outcomes included hospital length of stay, 30-day major complication rates, dischar

39 OR = 1.11; 95% CI, 0.92-1.35; P = 0.27) and length of stay (-4% for nonoverlapping; 95% CI, -4% to -

40 oup had a lower adjusted intensive care unit length of stay (5.3 days [95% CI, 4.2-6.7] versus 9.19 d

41 CI, $93 to $154), significantly longer mean length of stay (5.64 days vs 5.21 days; adjusted differe

42 urgical complications (6.6% vs 9.4%), median length of stay (6 days vs 6 days), readmission (1.9% vs

43 equirement, intensive care unit and hospital length of stay (6.0 versus 6.5 days, P<0.001), and combi

44 CI 1.2-3.2; P = 0.005) and required greater length of stay (7 versus 6 days; RR 1.15; 95% CI 1.1-1.1

45 vs 15% for the placebo group, P = .67), ICU length of stay (8 days for the ganciclovir group vs 8 da

46 $26,604 vs $24,263; P = 0.005), 12.4% longer length of stay (95% CI 2.3%-23.5%; adjusted means 5.9 vs

47 302) reported significantly reduced hospital length of stay (absolute difference, 1.9 days; 95% CI, 0

48 The length of stay according to the application was positive

49 primary outcomes were hospital mortality and length of stay adjusted by demographics and comorbiditie

50 ds of life-threatening disease and prolonged length of stay (adjusted OR, 2.1; 95% CI, 1.0-4.5; P = .

51 We compared outcomes mortality and length of stay after adjustment for registry-predicted r

52 Length of stay after childbirth is very variable between

53 We described length of stay after facility delivery in 92 countries.

54 Mean (SD) length of stay after S-ICD implantation was comparable t

55 Postoperative outcomes included length of stay, all-cause 30-day readmission rate, posto

56 Relative to SAVR, TAVR reduced initial length of stay an average of 4.4 days, decreased the nee

57 Hospital length of stay and 1-year readmission with inflammatory

58 anning and identifying unexpectedly long ICU length of stay and across ICUs for benchmarking, with lo

59 Median length of stay and cost of readmissions were 4 days (int

60 tality; secondary outcomes included hospital length of stay and cost.

61 Increased length of stay and costs of care were associated with As

62 SL had longer length of stay and higher total cost (P < 0.001).

63 POCT was also associated with a reduced length of stay and improved influenza detection and anti

64 Improvements in length of stay and in operative mortality among elderly

65 rmine whether use of a CDSS reduces hospital length of stay and in-hospital mortality for patients wi

66 nical pathways for suspected ACS reduced the length of stay and increased the proportions of patients

67 Hospital length of stay and injury insurance were nonmodifiable f

68 onscious sedation is associated with briefer length of stay and lower in-hospital and 30-day mortalit

69 sis and multiorgan failure, ICU and hospital length of stay and mortality, adverse events, and time t

70 Hospital length of stay and postoperative complication rates were

71 absolute and relative decreases in hospital length of stay and postoperative complication rates.

72 e benefits of laparoscopy, including reduced length of stay and quicker opioid independence.

73 gy consultations on metrics such as hospital length of stay and readmission rates remains unknown.

74 ifferences were observed in ICU and hospital length of stay and several other secondary outcomes.

75 al fibrillation with outcomes, including ICU length of stay and survival.

76 e also examined associations between hospice length of stay and these outcomes among hospice enrollee

77 as associated with significant reductions in length of stay and total charges, a finding that has tre

78 Secondary outcomes included hospital length of stay and total charges.

79 Length of stay and total health care costs were compared

80 sfunction may both be associated with longer length of stay and worse outcome.

81 included inpatient Medicare Part B spending, length of stay, and 30-day readmissions.

82 discussion of patient preferences, hospital length of stay, and 90-day survival.

83 ons, comorbidity burden, loop stoma, shorter length of stay, and age.

84 cal outcomes of hospital length of stay, ICU length of stay, and alcohol withdrawal syndrome complica

85 Secondary endpoints were antibiotic use, length of stay, and antibiotic side-effects.

86 capacity, identifying unexpectedly long ICU length of stay, and benchmarking ICUs.

87 Rate, length of stay, and charges for pediatric hospitalizatio

88 To examine risk factors, mortality, length of stay, and cost associated with admission to th

89 istically significant increase in mortality, length of stay, and cost.

90 th of stay in the ICU, total hospitalization length of stay, and cost.

91 rforation, negative appendectomy, morbidity, length of stay, and cost.

92 lization at a different hospital, mortality, length of stay, and costs during rehospitalization.

93 In-hospital outcomes (mortality, length of stay, and discharge destination) and postdisch

94 Advanced age, length of stay, and duration of life support were the le

95 to be associated with reduced mortality, ICU length of stay, and duration of mechanical ventilation.

96 ays, estimated incidence from prevalence and length of stay, and generated national estimates.

97 its association with in-hospital mortality, length of stay, and health care cost.

98 ge, dialysis, hepatic encephalopathy, longer length of stay, and higher white blood cell count or MEL

99 the ED, missed intra-abdominal injuries, ED length of stay, and hospital charges.

100 spitalization for AF, in-hospital mortality, length of stay, and hospital payments.

101 mechanical ventilation, intensive care unit length of stay, and in-hospital mortality were similar b

102 r second dose delay and increased mortality, length of stay, and mechanical ventilation requirement.

103 Mechanical ventilation duration, ICU length of stay, and mortality did not differ between the

104 risk factors, comorbidities, costs of care, length of stay, and mortality in hospitalized U.S. child

105 to critical care, acute hospital mortality, length of stay, and other variables routinely collected

106 treatment, reinterventions, rescue surgery, length of stay, and overall treatment success.

107 l mortality rates, 30-day readmission rates, length of stay, and patient satisfaction scores for comm

108 ortality, in-hospital mortality, medical ICU length of stay, and post-ICU discharge hospital length o

109 ated blood loss, intraoperative transfusion, length of stay, and postoperative complications (all hig

110 w of ICU utilization rates, hospital and ICU length of stay, and severity-adjusted mortality rates.

111 and rapidly fatal McCabe scores), prolonged length of stay, and the use of invasive medical devices.

112 ignificantly decrease the incidence of POAF, length of stay, and total variable cost in patients unde

113 To evaluate trends in mortality, hospital length of stay, and unplanned readmission in Canadian tr

114 hour mortality, hospital length of stay, ICU length of stay, and ventilator-free days.

115 ity, major adverse event, prolonged hospital length of stay, and wound infection/dehiscence).

116 al success, intensive care unit and hospital length-of-stay, and rates of discharge to home.

117 disease characteristics, cultured pathogens, lengths of stay, and short-term and long-term mortality.

118 spital, 90-day, and 1-year mortality; longer length of stay; and several other important adverse outc

119 ingle doses or brief courses of antibiotics, length of stay, antiviral use, isolation facility use, a

120 ciation between AKI, mortality, and hospital length of stay are limited due to the small sample size

121 who died at a different hospital had shorter length of stay (aRR, 0.80; 95% CI, 0.70-0.92; P = 0.001)

122 different hospital had a modest increase in length of stay (aRR, 1.06; 95% CI, 1.01-1.11; P = 0.009)

123 plication was positively correlated with the length of stay ascertained via the electronic medical re

124 P = 0.008), the proportion of patients with length of stay at least 5 days (OR 0.75; 95% CI, 0.67-0.

125 days, mean ICU length of stay, mean hospital length of stay, bed elevation to >/=30 degrees , venous

126 t decrease in ICU and hospital mortality and length of stay between 1997 and 2013 despite little chan

127 and September 30, 2014, with a postoperative length of stay between 2 and 30 days.

128 in the United States and to compare hospital length of stay between patients with choledocholithiasis

129 There was no difference in the median length of stay between the 2 groups.

130 used interventions resulted in decreased ICU length of stay but not mortality.

131 = 0%), but there was a mean decrease in ICU length of stay by 1.21 days (n = 3 studies; 95% CI, -2.2

132 ed with a reduction in the adjusted hospital length of stay by 2.64 days (95% CI, 1.75-3.53 days; P <

133 ed included patient demographics, diagnoses, length of stay, circumstances, and outcome of admission.

134 luded age, sex, race/ethnicity, month, year, length of stay, comorbidities, and hospital.

135 as to describe the incidence, costs of care, length of stay, comorbidities, and mortality of SJS and

136 cantly higher PICU mortality and longer PICU length of stay, compared with index admissions (4.0% vs

137 demographic data, hospital characteristics, length of stay, complications (surgical and systemic), a

138 Longer length of stay contributed to regional cost variation an

139 endpoints included SSI incidence at 4 days, length of stay, cosmetic outcome, and patient satisfacti

140 ntilation, pneumonia, myocardial infarction, length of stay, cost, and mortality, and also a lower li

141 03 hours (95% CI, -8.60 to -1.45 hours), and length of stay decreased by -2.48 days (-3.90 to -1.06 d

142 decreased by 44% in younger children, and ED length of stay decreased by 33 min in older children).

143 In-hospital mortality, 30-day mortality, and length of stay decreased during the study period.

144 Hospital length of stay decreased from 44 to 36 days (p < 0.05).

145 ICU length of stay decreased from 6.5 to 5.8 days in the imm

146 During the same time period, mean hospital length of stay decreased; nontargeted conditions (10.4-8

147 )(95% CI: -1.3, 0.0 g . kg(-1). d(-1))], and length of stay [Delta = 2.0 d (95% CI: -1.7, 5.8 d)] in

148 3-11]; P = .01), while median (IQR) hospital length of stay did not differ significantly (22 [10.25-3

149 Our secondary outcomes were ICU and hospital length of stay, duration of mechanical ventilation, and

150 Furthermore, length of stay during index hospitalization was directly

151 early discharge (</=48 hours), and decrease length of stay for all patients.

152 The mean hospital length of stay for CRT decreased, while mean CRT-associa

153 Efforts to safely reduce length of stay for emergency department patients with sy

154 Reduced length-of-stay for inpatient surgical care requires the

155 Reduced length-of-stay for inpatient surgical care requires the

156 here was a significant difference in average length of stay, from 4.8 days +/- 7.0 to 4.2 days +/- 6.

157 with patients greater than 66 years with ICU length of stay greater than 2 weeks who sustained the wo

158 than or equal to 18 years old with expected length of stay greater than or equal to 24 hours consecu

159 pital mortality or intensive care unit [ICU] length of stay >/=3 days) more common in sepsis than unc

160 edicare-payment eligibility to patients with length of stay >/=3days (SNF requirement) and >/=1 "pres

161 95% CI, 1.88-2.56), greater length of stay (length of stay >4 days OR, 1.38; 95% CI, 1.29-1.47), and

162 Length of stay >5 days during index hospitalization (haz

163 3.20; 95%CI, 1.18-8.68; P=.02) and hospital length-of-stay >/=3 days (OR, 4.14; 95%CI, 2.08-8.24; P<

164 ve care use (Pinteraction =.02) and hospital length-of-stay >/=3 days (Pinteraction =.03).

165 d to pregnancy, urology procedures, and with lengths of stay >30 days.

166 oracic intensive care unit and its effect on length of stay has not been investigated.

167 had greater in-hospital mortality, hospital length of stay, hemorrhage requiring transfusion, and pe

168 ause mortality, 30-day readmission, hospital length of stay, hospital cost, and discharge disposition

169 he duration of mechanical ventilation or ICU length of stay; however, those with indirect lung injury

170 postoperative mortality, ICU admission, and length of stay (ICU and hospital).

171 Clinical outcomes of hospital length of stay, ICU length of stay, and alcohol withdraw

172 utcomes included 48-hour mortality, hospital length of stay, ICU length of stay, and ventilator-free

173 s, early feeding was associated with reduced length of stay in 4 of 7 studies (including 2 of 3 with

174 We further evaluated length of stay in a cohort matched by propensity to rece

175 bacterial pathogens increases with hospital length of stay in burn patients.

176 The length of stay in hospital was similar for both groups (

177 he hypothesis that risk aversion extends the length of stay in the dwelling and, by extension, in the

178 Prespecified secondary outcomes were length of stay in the ICU and hospital, incidence of bar

179 Secondary outcomes included length of stay in the ICU, total hospitalization length

180 econdary outcome was all-cause mortality and length of stay in the intensive care unit.

181 ation of invasive mechanical ventilation and length of stay in the intensive-care unit were significa

182 Lengths of stay in ICU were a mean of 33.8 hours (median

183 f mechanical ventilation or ICU and hospital lengths of stay in recipients, but the stress index duri

184 .4, 99% CI: 3.2, 3.6), longer intensive care length of stay (incidence rate ratio = 2.0, 99% CI: 1.9,

185 gnificantly associated with shorter adjusted length of stay (incidence rate ratio, 0.86; 95% CI, 0.75

186 icant differences in duration of bacteremia, length-of-stay, infection-related length-of-stay, or rea

187 nned readmissions within 30 days, (iii) long length of stay, (iv) healthcare acquired infections, and

188 United States as well as the benefit to the length of stay LCBDE+LC has over ERCP+LC.

189 atio [OR], 2.19; 95% CI, 1.88-2.56), greater length of stay (length of stay >4 days OR, 1.38; 95% CI,

190 Patients less than 42 years with ICU length of stay less than 2 weeks had the best function a

191 spitals are increasingly motivated to reduce length of stay (LOS) after lung cancer surgery, yet it i

192 y postoperative morbidity, and postoperative length of stay (LOS) among patients undergoing abdominal

193 Secondary outcomes included length of stay (LOS) and postoperative complications (in

194 Hospital length of stay (LOS) and whether its association with pa

195 een surgical episode payments and hospitals' length of stay (LOS) mode were evaluated among a risk an

196 In-hospital mortality or ICU length of stay (LOS) of 3 days or more was a composite s

197 causes (total and 30 days after infection), length of stay (LOS), and 5 indicators of morbidity: int

198 ssociated with longer kidney transplant (KT) length of stay (LOS), and modifies the association betwe

199 duration, such as intensive care unit (ICU) length of stay (LOS), are widely used in randomized clin

200 econdary diagnoses, vital sign measurements, length of stay (LOS), hospital readmissions, and mortali

201 ovascular illnesses with outcomes, including length of stay (LOS), mortality, and hospital readmissio

202 rtality and the secondary outcome was median length of stay (LOS).

203 table delirium, which extends their hospital length of stay (LOS).

204 5.98 h; P < 0.001), and the overall hospital length of stay (LOS; 15.03 versus 9.02 days; P = 0.021).

205 e unit (ICU) admission, and hospital and ICU lengths of stay (LOS) were outcome measures for severity

206 nship between BMI and CAP outcomes (hospital length of stay [LOS], intensive care unit [ICU] admissio

207 atients below this threshold had shorter ICU length of stay, lower incidence of acute kidney injury,

208 Among patients with postoperative length of stay </=10 days and no unplanned readmission,

209 .63]; p < 0.0001) and decreased the hospital length of stay (mean difference, -5.44 d; 95% CI, -9.28

210 fection, mean ventilator-free days, mean ICU length of stay, mean hospital length of stay, bed elevat

211 tients without cancer had longer medical ICU length of stay (median, 5 vs 4 d; p = 0.0495), used mech

212 linical care, including use of resources; ED length of stay; missed intra-abdominal injuries; or hosp

213 ransfused," without any detectable change in length-of-stay, morbidity or mortality.

214 al of 1,042,710 adult patient stays with ICU length of stay more than 24 hours, of which 74,771 were

215 Hospital length of stay, mortality, and 1 month readmissions decr

216 nce of secondary bacteremia or fungemia, ICU length of stay, mortality, and ventilator-free days (VFD

217 mong primary outcomes except for medical ICU length of stay (nurse practitioner-resident-staffed 7.9

218 atio 4.03, African American odds ratio 3.08, length of stay odds ratio 1.11; and hernia recurrence: p

219 ied: porcine cadaveric mesh odds ratio 2.82, length of stay odds ratio 1.11; complications: drinker o

220 ficantly less likely to experience prolonged length of stay (odds ratio [OR], 0.50; 95% CI, 0.26-0.97

221 io, 1.41; 95% CI, 0.87-2.28; p = 0.164), ICU length of stay (odds ratio, 0.90; 95% CI, 0.63-1.30; p =

222 ged 15 to 29 years, and 33 995 (70.0%) had a length of stay of 30 days or less.

223 ed to the pediatric intensive care unit with length of stay of 4 hours or more were evaluated (4560 p

224 rol and less narcotic use, without increased length of stay or complications.

225 o significant differences in ICU or hospital length of stay or mortality.

226 per point), and loop stoma (OR 2.2); longer length of stay (OR 0.5) and age 65 years or older (OR 0.

227 ollowing both surgeries, including prolonged length of stay (OR, 1.37; 95% CI, 1.11-1.70) following O

228 There were no differences in morbidity, length of stay, or cost.

229 planning, identifying unexpectedly long ICU length of stay, or for benchmarking purposes.

230 acteremia, length-of-stay, infection-related length-of-stay, or readmission were observed between the

231 iction models of inpatient deaths, prolonged length-of-stay outliers, 90-day postdischarge deaths, an

232 ICU length of stay (p = 0.031) and hospital length of stay (p < 0.001) remained after adjustment for

233 justment, MI-LAR was associated with shorter length of stay (P < 0.001), but similar rates of positiv

234 ative complications (P < 0.001) and hospital length of stay (P < 0.001).

235 The impact of the study intervention on ICU length of stay (p = 0.031) and hospital length of stay (

236 ve pulmonary disease (p = 0.83), or hospital length of stay (p = 0.12).

237 anical ventilation and with ICU and hospital lengths of stay (P < 0.05).

238 14.5%, IMG: 14.3%; P = 0.032), and prolonged length of stay (pLOS) (USMG: 22.7%, IMG: 22.8%; P = 0.35

239 ssociations with risk-adjusted postoperative length of stay (pLOS).

240 e interval 0.657-0.896, P = 0.001); hospital length-of-stay, postoperative morbidity, and postoperati

241 dies on the development or validation of ICU length of stay prediction models.

242 DATA EXTRACTION: Clinicians use ICU length of stay predictions for planning ICU capacity, id

243 reeclampsia, congestive heart failure (CHF), length of stay, preterm labor, anemia complicating pregn

244 97 vs 2.79 +/- 0.73; P = 0.009) and hospital length of stay (r = 0.583, P = 0.003).

245 onstrated via a significant correlation with length of stay (r = 0.586, P < .0001).

246 Inpatient length of stay ranged from 1 to 425 days (median, 24 day

247 es in lymph node harvest, margin positivity, length of stay, readmission rate, 30-day mortality, or o

248 costs, despite being associated with longer length of stay (relative risk, 1.17; 95% CI, 1.09-1.26;

249 Median hospital length of stay remained unchanged at 3.0 (interquartile

250 ntervention period, median SICU and hospital length of stay remained unchanged.

251 mbining the load of exposure to carriers and length of stay seemed to have an additive effect on the

252 Physicians using these models to predict ICU length of stay should interpret them with reservation.

253 They have shorter ICU lengths of stay than actively managed patients, suggesti

254 In a cost-benefit analysis which considered length of stay, the net monetary benefit for the care bu

255 ncluded ICU and hospital mortality rates and length of stay, time to broad-spectrum antiinfective the

256 h, major medical and surgical complications, length of stay, total charges, and discharge disposition

257 ssociated with mortality, prolonged hospital length of stay, use of dialysis, and subsequent CKD.

258 rates were correlated with changes in index length of stay, use of observation status, or discharge

259 sociation between these groups and patients' length of stay using multivariable Cox proportional haza

260 $5912 per patient; P < .001); total hospital length of stay varied by 47% (1.5 vs 2.2 days; P < .001)

261 decrease duration of mechanical ventilation, length of stay, ventilator-associated events, mortality,

262 The mean (SD) length of stay was 11 (5) days, and the all-cause 30-day

263 The median length of stay was 2 days and mortality was 0.2%.

264 Median length of stay was 4 days (range 2 to 6 days).

265 ation for bleeding in 2 patients, and median length of stay was 4 days [3-5.5 days].

266 The median length of stay was 4 days, with the longest duration in

267 ars; 187 [48%] women), median (IQR) hospital length of stay was 6 (3-10) days.

268 The mean ED length of stay was 6.03 hours in the FAST group and 6.07

269 Median length of stay was 7 and 5 days for PD and DP, respectiv

270 Median length of stay was 7 days (range 4 to 50).

271 Median length of stay was 8 days.

272 Change in adjusted hospital length of stay was also significant (incidence rate rati

273 Post-transplant length of stay was also similar between the 2 groups.

274 Median ICU length of stay was between 2 and 6.9 days.

275 A significant difference in length of stay was found between the West and Northeast

276 A significant, clinically unimportant longer length of stay was found for high inequality (2.5 days;

277 PICU length of stay was increased in children with delirium (

278 Median postrandomization ICU length of stay was lower in the high-flow group, 3 days

279 dence interval, CI 1.23-3.73; P = 0.007) and length of stay was no different (+1% for nonoverlapping

280 oup (12% versus 21%, P < 0.01), and the mean length of stay was reduced, although the difference was

281 The unadjusted median hospital length of stay was shorter for patients treated with LCB

282 Mean length of stay was shorter in the POCT group (5.7 days [

283 The median (interquartile range) ICU length of stay was significantly less for the interventi

284 Length of stay was significantly reduced in the negative

285 Median hospital length of stay was significantly shorter in alemtuzumab

286 Length of stay was unexpectedly higher in the care bundl

287 was associated with reduced duration of ICU length of stay (weighted mean difference, -1.16 d [95% C

288 Clinical failure and length of stay were also analyzed.

289 ia, decubitus ulcer, and death) and hospital length of stay were compared across quartiles of risk-ad

290 Mortality, complications, and prolonged length of stay were compared between IMG and USMG surgeo

291 independent variables other than age and for length of stay were found.

292 vidual SSI types, time to SSI diagnosis, and length of stay were not different between the 2 arms.

293 ter matching, no differences in mortality or length of stay were observed.

294 ative time, postoperative complications, and length of stay were recorded.

295 Adjusted 1-year mortality and length of stay were significantly higher in patients wit

296 Increasing age and length of stay were strongly associated with all-cause r

297 ocedural adverse events with longer hospital length of stay, when compared with those without CKD.

298 mortality, fewer complications, and shorter length of stays, which might be explained by the electiv

299 othesis was that by using this strategy, the length-of-stay would be reduced by 10%.

300 and outcomes of the program (e.g., decreased length of stay) would have a significant positive econom